Killingworth, CT, United States of America

Richard A Flavell

USPTO Granted Patents = 51 (Patent Applications = 15)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 25 (Patent Applications = 31)

Average Co-Inventor Count = 5.4

ph-index = 13

Forward Citations = 371(Granted Patents)

Forward Citations (Not Self Cited) = 158(Dec 10, 2025)

Location History:

Killingworth, CT (US) (1997 - 2005)
Guildford, CT (US) (2018)
Guillford, CT (US) (2020 - 2021)
Guilford, CT (US) (2005 - 2023)

Company Filing History:

Regeneron Pharmaceuticals, Inc.

patents

20 out of 20

Institute for Research in Biomedicine (irb)

patents

4. 3 out of 197

Oklahoma Medical Research Foundation

patents

5. 1 out of 56

Institute for Research in Biomedicine

patents

6. 1 out of 1,552

University of Massachusetts

patents

7. 1 out of 50

Ospedale San Raffaele S.r.l.

Vertex Pharmaceuticals, Inc.

patents

10. 1 out of 443

The Broad Institute, Inc.

patents

11. 1 out of 8,373

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Genetically Modified Mice

Nanolipogel Vehicles

Innate Lymphoid Cells

Humanized M-CSF Mice

Transgenic Animals

Alzheimer's Disease Therapy

Universal Donor Cells

Lyme Disease Diagnosis

B. Burgdorferi Polypeptides

Immune Response Modulation

Glucose Metabolism

Pharmaceutical Delivery

51 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12402611 - Genetically modified mice and engraftment (2025-09-02),

2. 12402610 - Methods and compositions for modulating innate lymphoid cell pathogenic effectors (2025-09-02),

3. 12156939 - Nanolipogel vehicles for controlled delivery of different pharmaceutical agents (2024-12-03),

4. 12127537 - Genetically modified non-human animals and methods of use thereof (2024-10-29),

5. 12127536 - Humanized M-CSF mice (2024-10-29),

6. 11778995 - Genetically modified non-human animals and methods of use thereof (2023-10-10),

7. 11766032 - Genetically modified non-human animals expressing human EPO (2023-09-26),

8. 11576356 - Genetically modified non-human animals and methods of use thereof (2023-02-14),

9. 11299790 - Compositions and methods for identifying secretory antibody-bound microbes (2022-04-12),

10. 11173119 - Nanolipogel vehicles for controlled delivery of different pharmaceutical agents (2021-11-16),

11. 11051499 - Genetically modified mice and engraftment (2021-07-06),

12. 11026408 - Genetically modified non-human animals and methods of use thereof (2021-06-08),

13. 10925953 - Compositions and methods for treating an inflammatory disease or disorder (2021-02-23),

14. 10785968 - Genetically modified non-human animals and methods of use thereof (2020-09-29),

15. 10785966 - Humanized M-CSF mice (2020-09-29),

Title: The Innovative Journey of Richard A. Flavell

Introduction:

Richard A. Flavell, a distinguished inventor hailing from Killingworth, CT (US), has made significant contributions to the field of innovations and patents.

Latest Patents:

1. Patent 1: Title of Patent 1

2. Patent 2: Title of Patent 2

3. Patent 3: Title of Patent 3

Career Highlights:

Richard A. Flavell boasts a remarkable career marked by numerous achievements in the realm of inventions and patents. With a keen eye for innovation, he has successfully patented several groundbreaking technologies that have revolutionized their respective industries.

Collaborations:

Throughout his career, Richard A. Flavell has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His collaborative efforts have resulted in the development of cutting-edge technologies that have garnered international acclaim.

Conclusion:

In conclusion, Richard A. Flavell stands as a visionary inventor whose relentless pursuit of innovation has left an indelible mark on the world of patents. His groundbreaking inventions continue to inspire future generations of inventors to push the boundaries of what is possible in the realm of technology.

This text is generated by artificial intelligence and may not be accurate.